Higher-Risk MDS Satellite Symposium

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.